Ropes & Gray LLP’s dominant life sciences offering is reflected in its venture capital practice and it supports life sciences start-ups and later-stage entities on financings, M&A, and exit transactions. The group also undertakes work for venture capital funds, private equity clients, and strategic investors, including the venture capital arms of major pharmaceutical multinationals. A trio of Boston-based partners co-head the team: Bradford Flint advises life sciences and technology companies and investors on an array of formation, financing, and corporate matters, while Marc Rubenstein and Rajarshi Banerjee specialize in life sciences and IP-related work. Private funds co-head Melissa Bender is also noted; she operates from San Francisco and Silicon Valley.
Legal 500 redaktioneller Kommentar
- Profil
Referenzen
Unabhängig vom Legal 500-Forschungsteam zusammengestellt.
- ‘The lawyers at the venture capital and emerging companies practice at Ropes & Gray are exceptional. They have deep knowledge and experience in both the venture capital industry as well as the broader biotech ecosystem and in addressing specific needs of large multinationals.’
- ‘Ropes & Gray have supported us for some time now across all our corporate legal priorities, particularly executing fundraising and major licensing transactions. Ropes has effectively supported our growth trajectory as we mature as a company.’
Kernmandanten
- Gilgamesh Pharmaceuticals
- MOMA Therapeutics
- Haveli Investment Management LLC
- Kailera Therapeutics, Inc.
- CAMP4 Therapeutics
- Perceptive Discovery Fund LP US
- RTW Investments LP
- Sands Capital Management LP
- AvenCell Therapeutics
- NorthPond Ventures LLC
Anwält*innen
Praxisleitung
Bradford Flint; Marc Rubenstein; Rajarshi Banerjee
Weitere Kernanwält*innen
Melissa Bender